The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Seminars in Cancer Biology

• Publication date

  2015-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.semcancer.2015.04.009PMID 25963298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.

  2015cited by this paper
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

  2015cited by this paper
• Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.

  2015cited by this paper
• Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting

  2015cited by this paper
• Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia

  2014cited by this paper
• Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.

  2014cited by this paper
• The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.

  2014cited by this paper
• Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia

  2014cited by this paper
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

  2014cited by this paper
• Acquired initiating mutations in early hematopoietic cells of CLL patients.

  2014cited by this paper
• An Entity Evolving into a Community: Defining the Common Ancestor and Evolutionary Trajectory of Chronic Lymphocytic Leukemia Stereotyped Subset #4

  2014cited by this paper
• Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  2014cited by this paper
• The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia

  2014cited by this paper
• SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

  2014cited by this paper
• High‐throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications

  2014cited by this paper
• How the microenvironment wires the natural history of chronic lymphocytic leukemia.

  2014cited by this paper
• On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort

  2014cited by this paper
• Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data

  2014cited by this paper
• A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact

  2014cited by this paper
• Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia.

  2014cited by this paper
• Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  2014cited by this paper
• Recurrent mutations refine prognosis in chronic lymphocytic leukemia

  2014cited by this paper
• Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  2014cited by this paper
• Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

  2014cited by this paper
• The impact of SF3B1 mutations in CLL on the DNA-damage response

  2014cited by this paper
• Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

  2014cited by this paper
• Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

  2014cited by this paper
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

  2014cited by this paper
• Monoclonal B cell lymphocytosis and "in situ" lymphoma.

  2014cited by this paper
• Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution.

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

  2014cited by this paper
• The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.

  2014cited by this paper
• Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

  2014cited by this paper
• ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

  2014cited by this paper
• Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

  2014cited by this paper
• IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria

  2014cited by this paper
• Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.

  2014cited by this paper
• Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders

  2014cited by this paper
• Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study

  2014cited by this paper
• Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

  2014cited by this paper
• Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia

  2014cited by this paper
• MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

  2014cited by this paper
• 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments

  2013cited by this paper
• Igs Expressed by Chronic Lymphocytic Leukemia B Cells Show Limited Binding-Site Structure Variability

  2013cited by this paper
• NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

  2013cited by this paper
• POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia

  2013cited by this paper
• Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

  2013cited by this paper
• Temporal Dynamics of Clonal Evolution in Chronic Lymphocytic Leukemia with Stereotyped IGHV4-34/IGKV2-30 Antigen Receptors: Longitudinal Immunogenetic Evidence

  2013cited by this paper
• A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient

  2013cited by this paper
• B-cell receptor signaling as a driver of lymphoma development and evolution.

  2013cited by this paper
• A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi

  2013cited by this paper
• The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

  2013cited by this paper
• Differential microRNA Profiles and Their Functional Implications in Different Immunogenetic Subsets of Chronic Lymphocytic Leukemia

  2013cited by this paper
• Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

  2013cited by this paper
• Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome

  2013cited by this paper
• Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients

  2013cited by this paper
• Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2

  2013cited by this paper
• Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

  2013cited by this paper
• A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

  2013cited by this paper
• Uncovering the DNA methylome in chronic lymphocytic leukemia

  2013cited by this paper
• Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

  2013cited by this paper
• Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

  2013cited by this paper
• This information is current as Structure Variability Binding-SiteLeukemia B Cells Show Limited Igs Expressed by Chronic Lymphocytic

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients

  2013cited by this paper
• NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia

  2013cited by this paper
• Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

  2013cited by this paper
• Antigen selection in B-cell lymphomas--tracing the evidence.

  2013cited by this paper
• Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

  2013cited by this paper
• Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse

  2012cited by this paper
• ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

  2012cited by this paper
• Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

  2012cited by this paper
• Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles

  2012cited by this paper
• Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

  2012cited by this paper
• Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.

  2012cited by this paper
• ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

  2012cited by this paper
• Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

  2012cited by this paper
• Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

  2012cited by this paper
• Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.

  2012cited by this paper
• Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells.

  2012cited by this paper
• Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

  2012cited by this paper
• NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.

  2012cited by this paper
• Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.

  2012cited by this paper
• NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

  2012cited by this paper
• Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

  2012cited by this paper
• MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

  2012cited by this paper
• Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia

  2012cited by this paper
• Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia

  2012cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

  2012cited by this paper
• Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

  2012cited by this paper
• New Mutations in Chronic Lymphocytic Leukemia Identified by Target Enrichment and Deep Sequencing

  2012cited by this paper
• Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors

  2012cited by this paper
• Frequent pathway mutations of splicing machinery in myelodysplasia

  2011cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• Oncogenically active MYD88 mutations in human lymphoma

  2011cited by this paper
• Treating chronic lymphocytic leukemia with thalidomide and lenalidomide

  2011cited by this paper

• IκBε deficiency accelerates disease development in chronic lymphocytic leukemia

  2024cites this paper
• Immunoglobulin genes and stereotyped antigenic receptors in chronic lymphocytic leukemia and other lymphoproliferative diseases

  2023cites this paper
• Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study

  2022cites this paper
• Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity

  2022cites this paper
• TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia

  2021cites this paper
• Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

  2020cites this paper
• Chronic Lymphocytic Leukemia

  2020cites this paper
• Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression

  2020cites this paper
• Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

  2020cites this paper
• High multiplex analysis of the immune microenvironment in bone marrow trephine samples using GeoMX™ digital spatial profiling

  2020cites this paper
• Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

  2020cites this paper
• Targeting the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia

  2020cites this paper
• CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation.

  2020cites this paper
• Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors

  2019cites this paper
• Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.

  2019cites this paper
• p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia

  2019cites this paper
• Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.

  2019cites this paper
• Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia.

  2018cites this paper
• Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia.

  2018cites this paper
• Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation.

  2018cites this paper
• Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

  2018cites this paper
• Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in Chronic Lymphocytic Leukemia

  2017cites this paper
• Tp53 gene p72R polymorphism in chronic lymphocytic leukemia: incidence and clinical significance amongst cases with unmutated immunoglobulin receptors

  2017cites this paper
• Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal

  2017cites this paper
• Targeting of B‐cell receptor signalling in B‐cell malignancies

  2017cites this paper
• Antigen receptor stereotypy in chronic lymphocytic leukemia

  2017cites this paper
• Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations

  2017cites this paper
• The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia

  2017cites this paper
• Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor

  2017cites this paper
• Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies

  2017cites this paper
• Prognostic impact of NOTCH 1 , MYD 88 , and SF 3 B 1 mutations in Polish patients with chronic lymphocytic leukemia

  2017cites this paper
• Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.

  2017cites this paper
• Chapter 26 – Idelalisib

  2017cites this paper
• Chapter 27 – Ibrutinib

  2017cites this paper
• Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification

  2017cites this paper
• EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

  2017cites this paper
• Separation of cell survival, growth, migration, and mesenchymal transdifferentiation effects of fibroblast secretome on tumor cells of head and neck squamous cell carcinoma

  2017cites this paper
• Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients

  2016cites this paper
• The chronic lymphocytic leukaemia lymph node microenvironment

  2016cites this paper
• ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres

  2016cites this paper
• Preview : Published ahead of advance online publication EGR 2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

  2016cites this paper
• Exploring next-generation sequencing in chronic lymphocytic leukemia

  2016cites this paper
• Reappraising prognosis in chronic lymphocytic leukemia

  2016cites this paper
• Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?

  2016cites this paper
• B-cell malignancies: All roads lead to NF-κB activation.

  2016cites this paper
• Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond

  2016cites this paper
• Chronic lymphocytic leukemia: Time to go past genomics?

  2016cites this paper
• Lymphomas and microenvironment: Impact on lymphomagenesis. Foreword.

  2015cites this paper
• Chronic lymphocytic leukemia: looking into the dark side of the genome

  2015cites this paper